FDA Alerts

The FDA has expanded the use of Opdivo (nivolumab) for the treatment of patients with urothelial carcinoma, the most common form of bladder cancer.

The FDA approved Symbicort Inhalation Aerosol 80/4.5 for the treatment for the treatment of asthma in pediatric patients aged 6 to 12 years.

The FDA has approved AirDuo RespiClick and ArmonAir RespiClick for the treatment of adolescent and adult patients with asthma.

The FDA has approved Trulance (plecanatide) for the treatment of chronic idiopathic constipation in adults.

The FDA has approved Rhofade (oxymetazoline hydrochloride) cream, 1%, for the topical treatment of persistent facial erythema associated with rosacea.

The FDA approved Vantrela ER tablets for the management of severe pain requiring daily opioid treatment which alternative treatment options have proven inadequate.

The FDA has issued a warning of potential injury and death associated with the use of implantable infusion pumps in the magnetic resonance environment.

The FDA has approved a long-acting opioid painkiller designed to be difficult to crush, manipulate, and abuse.

The FDA has approved a new ointment for the treatment of mild-to-moderate eczema in patients aged 2 years and older.

Based on the results of a recent clinical trial, the FDA has decided to remove its black box warning from the label of Chantix (varenicline).